This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Onodera, Y.
Right arrow Articles by Sato, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Onodera, Y.
Right arrow Articles by Sato, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2423-2429, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Molecular Cloning of the gyrA and gyrB Genes of Bacteroides fragilis Encoding DNA Gyrase

Yoshikuni Onodera* and Kenichi Sato

New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo 134-8630, Japan

Received 12 January 1999/Returned for modification 19 April 1999/Accepted 16 July 1999

The genes encoding the DNA gyrase A and B subunits of Bacteroides fragilis were cloned and sequenced. The gyrA and gyrB genes code for proteins of 845 and 653 amino acids, respectively. These proteins were expressed in Escherichia coli, and the combination of GyrA and GyrB exhibited ATP-dependent supercoiling activity. To analyze the role of DNA gyrase in quinolone resistance of B. fragilis, we isolated mutant strains by stepwise selection for resistance to increasing concentrations of levofloxacin. We analyzed the resistant mutants and showed that Ser-82 of GyrA, equivalent to resistance hot spot Ser-83 of GyrA in E. coli, was in each case replaced with Phe. These results suggest that DNA gyrase is an important target for quinolones in B. fragilis.


* Corresponding author. Mailing address: New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., 16-13 Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan. Phone: 81-3-3680-0151, ext. 5812. Fax: 81-3-5695-8344. E-mail: onode90j{at}daiichipharm.co.jp.


Antimicrobial Agents and Chemotherapy, October 1999, p. 2423-2429, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Conrads, G., Citron, D. M., Goldstein, E. J. C. (2005). Genetic Determinant of Intrinsic Quinolone Resistance in Fusobacterium canifelinum. Antimicrob. Agents Chemother. 49: 434-437 [Abstract] [Full Text]  
  • Ricci, V., Peterson, M. L., Rotschafer, J. C., Wexler, H., Piddock, L. J. V. (2004). Role of Topoisomerase Mutations and Efflux in Fluoroquinolone Resistance of Bacteroides fragilis Clinical Isolates and Laboratory Mutants. Antimicrob. Agents Chemother. 48: 1344-1346 [Abstract] [Full Text]  
  • Peterson, M. L., Rotschafer, J. C., Piddock, L. J. V. (2003). Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. J Antimicrob Chemother 52: 481-484 [Abstract] [Full Text]  
  • Miyamae, S., Ueda, O., Yoshimura, F., Hwang, J., Tanaka, Y., Nikaido, H. (2001). A MATE Family Multidrug Efflux Transporter Pumps out Fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob. Agents Chemother. 45: 3341-3346 [Abstract] [Full Text]  
  • Oh, H., El Amin, N., Davies, T., Appelbaum, P. C., Edlund, C. (2001). gyrA Mutations Associated with Quinolone Resistance in Bacteroides fragilis Group Strains. Antimicrob. Agents Chemother. 45: 1977-1981 [Abstract] [Full Text]  
  • Ricci, V., Piddock, L. J. V. (2000). Accumulation of Norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 44: 2361-2366 [Abstract] [Full Text]  
  • Bachoual, R., Dubreuil, L., Soussy, C.-J., Tankovic, J. (2000). Roles of gyrA Mutations in Resistance of Clinical Isolates and In Vitro Mutants of Bacteroides fragilis to the New Fluoroquinolone Trovafloxacin. Antimicrob. Agents Chemother. 44: 1842-1845 [Abstract] [Full Text]